Dr. Tao, Mi-Hua 's orcid link picture Dr. Tao, Mi-Hua 's publons link picture

Dr. Tao, Mi-Hua

Research Fellow
  • 02-2789-9151 (L) (Lab) (Room No: N229)
  • 02-2652-3078 (O) (Office)
  • 02-2782-9142 (Fax)

  • Viral and Cancer Immunology
  • Viral and Cancer Immunotherapy
  • Vaccine Development
  • Gene Therapy

Education and Positions:
  • Ph.D.  Columbia University (Microbiology and Immunology).

    Postdoctoral Fellow.  Stanford University (Oncology)

  • 日常維護流程─ FACSCelesta
  • 感染性檢體流式細胞儀使用規則(2017)

  • Immunological tolerance is a common feature of chronic viral infections and malignant diseases. The research focus of my laboratory is to understand immunosuppressive mechanisms present in chronic hepatitis B (HBV) infections and in tumor microenvironment, and to develop novel therapeutic strategies to overcome immunosuppression and reactivate virus- and tumor-specific immunity for cure of chronic HBV and HBV-associated hepatocellular carcinoma and other cancers. For HBV studies, we have developed several HBV animal models, including HBV transgenic mice, human liver mice and human immune system mice (generated, respectively, by transplantation of human hepatocytes and/or human hematopoietic stem cells), and HBV pseudoviruses. For cancer immunotherapies, we have developed orthotopic liver cancer model, liver metastasis model of colon cancer, and oncogene-driven spontaneous breast cancer model to evaluate the therapeutic efficacy. Since outbreak of COVID-19 pandemic, we are actively engaged in developing COVID-19 vaccines (mRNA and recombinant RBD) and has transfered the technology to industry.  We also developed COVID-19 animal models to help researhers and biotech companies to evaluate efficacy of their drugs,  antibodies or vaccines against SARS-CoV-2 infection.

    Our Team
    Team photo

    Journal 88 Book 0

    1. Chung CY, Sun CP, Tao MH, Wu HL, Wang SH, Yeh SH, Zheng QB, Yuan Q, Xia NS, Ogawa K, Nakashima K, Suzuki T, Chen PJ Major HBV splice variant encoding a novel protein important for infection. Journal of hepatology S01688278(24), 116 (2024) [JCR] [WOS]
    2. Chou SC, Yen CT, Yang YL, Chen SH, Wang JD, Fan MN, Chen LF, Yu IS, Tsai DY, Lin KI, Tao MH, Wu JC, Lin SW Recapitulating the immune system of hemophilia A patients with inhibitors using immunodeficient mice. Thrombosis research 235, 155-163 (2024) [JCR] [WOS]
    3. Lu RM, Liang KH, Chiang HL, Hsu FF, Lin HT, Chen WY, Ke FY, Kumari M, Chou YC, Tao MH, Yi-Ling Lin, Wu HC Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. Heliyon 9(5), e15587 (2023) [JCR] [WOS]
    4. Sun CP, Chiu CW, Wu PY, Tsung SI, Lee IJ, Hu CW, Hsu MF, Kuo TJ, Lan YH, Chen LY, Ng HY, Chung MJ, Liao HN, Tseng SC, Lo CH, Chen YJ, Liao CC, Chang CS, Liang JJ, Draczkowski P, Puri S, Chang YC, Huang JS, Chen CC, Kau JH, Chen YH, Liu WC, Wu HC, Danny Hsu ST, Wang IH, Tao MH Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants. MOLECULAR THERAPY 31(11), 3322-3336 (2023) [JCR] [WOS]
    5. Kao CY, Pan YC, Hsiao YH, Lim SK, Cheng TW, Huang SW, Wu SM, Sun CP, Tao MH, Mou KY Improvement of Gene Delivery by Minimal Bacteriophage Particles. ACS nano 17(15), 14532-14544 (2023) [JCR] [WOS]
    6. Sung PS, Sun CP, Tao MH, Hsieh SL Inhibition of SARS-CoV-2-mediated thromboinflammation by CLEC2.Fc. EMBO molecular medicine 15(7), e16351 (2023) [JCR] [WOS]
    7. Huang HC, Wang SH, Fang GC, Chou WC, Liao CC, Sun CP, Jan JT, Ma HH, Ko HY, Ko YA, Chiang MT, Liang JJ, Kuo CT, Lee TA, Morales-Scheihing D, Shen CY, Chen SY, McCullough LD, Cui L, Wernig G, Tao MH, Lin YL, Chang YM, Wang SP, Lai YJ, Li CW Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. JOURNAL OF MEDICAL VIROLOGY Online ahead of print, Online ahead of print (2023) [JCR] [WOS]
    8. Kumari Monika, Lu Ruei-Min, Li Mu-Chun, Huang Jhih-Liang, Hsu Fu-Fei, Ko Shih-Han, Ke Feng-Yi, Su Shih-Chieh, Liang Kang-Hao, Yuan Joyce Pei-Yi, Chiang Hsiao-Ling, Sun Cheng-Pu, Lee I.-Jung, Li Wen-Shan, Hsieh Hsing-Pang, Tao Mi-Hua, Wu Han-Chung A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies Journal of Biomedical Science 29(1), 68 (2022-9-12) [JCR] [WOS]
    9. Lee IJ, Sun CP, Wu PY, Lan YH, Wang IH, Liu WC, Yuan JP, Chang YW, Tseng SC, Tsung SI, Chou YC, Kumari M, Lin YS, Chen HF, Chen TY, Lin CC, Chiu CW, Hsieh CH, Chuang CY, Cheng CM, Lin HT, Chen WY, Hsu FF, Hong MH, Liao CC, Chang CS, Liang JJ, Ma HH, Chiang MT, Liao HN, Ko HY, Chen LY, Ko YA, Yu PY, Yang TJ, Chiang PC, Hsu ST, Lin YL, Lee CC, Wu HC, Tao MH A booster dose of Delta x Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. Journal of Biomedical Science 29(1), 49 (2022) [JCR] [WOS]
    10. Jung Lee I, Lan YH, Wu PY, Wu YW, Chen YH, Tseng SC, Kuo TJ, Sun CP, Jan JT, Ma HH, Liao CC, Liang JJ, Ko HY, Chang CS, Liu WC, Ko YA, Chen YH, Sie ZL, Tsung SI, Lin YL, Hsuan Wang I, Tao MH A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. Emerging Microbes & Infections 1-45, 1-45 (2022) [JCR] [WOS]

    - POSTDOC -
    Sun, Cheng-Pu
    Chen, Bing-Mae
    Lan, Yu-hua